TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31562522

Group type: EXPERIMENTAL
Intervention: Education (1-standard deviation increase, equivalent to 3.6 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education (after adjusting for cognition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognition (1-standard deviation increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognition (after adjusting for education)
Number of subjects: 0
Study: 28645052

Group type: EXPERIMENTAL
Intervention: Active filtration (filter in)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham-mode filtration (filter out)
Number of subjects: 35
Study: 25380413

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23865673

Group type: EXPERIMENTAL
Intervention: Urinary protein:creatinine ratio (PrCr) measured using pyrocatechol violet assay
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Last urine sample before delivery
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Known normal pregnancy outcome
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pyrogallol red assay
Number of subjects: 160
Study: 21740236

Group type: EXPERIMENTAL
Intervention: Light-activated (LA) group using LED/laser energy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-activated (NA) group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Light-activated (LA) group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 19881236

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 36
Study: 16442954

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) 50 or 100 mug/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14711909

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Vasopressin followed by epinephrine
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 1186
Study: 11377597

Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 9471918

Group type: EXPERIMENTAL
Intervention: Women with osteoporosis (n=50)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 8098692

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: O2/air
Number of subjects: 40
Study: 2956923

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 175

Group type: COMPARATOR
Intervention: General, balanced anaesthesia
Number of subjects: 175
Study: 31957972

Group type: EXPERIMENTAL
Intervention: HPR switch group (ticagrelor)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: HPR nonswitch group (clopidogrel)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: non-HPR group
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1353
Study: 30696326

Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks of supervised training twice weekly including interval-based aerobic exercise and resistance training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 50
Study: 27933731

Group type: EXPERIMENTAL
Intervention: Incontinence-associated dermatitis (IAD) category 2
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Less mobility
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: More friction and shear issues
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: More erythema due to incontinence
Number of subjects: 381
Study: 25530107

Group type: EXPERIMENTAL
Intervention: Low dialysate sodium concentration (5 mEq/L below serum sodium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High dialysate sodium concentration (5 mEq/L above serum sodium)
Number of subjects: 16
Study: 23566075

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 900

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 900
Study: 20870757

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18492531

Group type: EXPERIMENTAL
Intervention: MAS063DP cream (n = 72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vehicle cream (n = 70)
Number of subjects: 142
Study: 16812973

Group type: COMPARATOR
Intervention: Efalizumab
Number of subjects: 4165

Group type: COMPARATOR
Intervention: Etanercept (1 mg/kg)
Number of subjects: 4165

Group type: COMPARATOR
Intervention: Etanercept (2 x 25 mg)
Number of subjects: 4165

Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg)
Number of subjects: 4165

Group type: EXPERIMENTAL
Intervention: Biological treatment
Number of subjects: 4165
Study: 11880085

Group type: EXPERIMENTAL
Intervention: Vasectomy plus irrigation of each vas deferens with sterile water
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard vasectomy
Number of subjects: 200
Study: 10717960

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2%, 0.4%, 0.6%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo-oxygen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14
Study: 7779574

Group type: EXPERIMENTAL
Intervention: 20 mg zinc gluconate twice (the evening before and 30 min before the test)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 7
Study: 1970070

Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement (250 ml, 20 g protein, 254 kcal) for a mean of 32 days
Number of subjects: 59
Study: 471861

Group type: EXPERIMENTAL
Intervention: Dextran 70 prophylaxis during operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 31869755

Group type: EXPERIMENTAL
Intervention: LTG group with drospirenon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LTG group with levonorgestrel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LTG group with gestoden
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with levonorgestrel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with drospirenon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LTG group during inactive pill with gestoden
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group on COC
Number of subjects: 20
Study: 31708182

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine (4 doses)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine (3 doses) plus 1 comparator vaccine dose
Number of subjects: 153

Group type: COMPARATOR
Intervention: Comparator vaccine doses (4 doses)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 153

Group type: COMPARATOR
Intervention: RTS,S/AS01-vaccinated immunogenicity controls with unknown or negative HIV status
Number of subjects: 153
Study: 29367471

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 156

Group type: COMPARATOR
Intervention: voglibose (0.2 mg/meal thrice daily)
Number of subjects: 156
Study: 26468636

Group type: EXPERIMENTAL
Intervention: 3D prints
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cadaveric materials
Number of subjects: 52

Group type: COMPARATOR
Intervention: Combined materials
Number of subjects: 52
Study: 24443059

Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-reactive protein (CRP)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Higher concentrations of interleukin-6 (IL-6)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-peptide
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Higher concentrations of non-HMW adiponectin
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Higher concentrations of GLDH
Number of subjects: 296
Study: 22616316

Group type: EXPERIMENTAL
Intervention: 0.1 mg of morphine (group M1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine (group M2)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 0.9 percent sodium chloride (saline, group S)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 0.5 percent levobupivacaine
Number of subjects: 112
Study: 20045479

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (single 6 mg dose)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day)
Number of subjects: 78
Study: 18022544

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (unconjugated and conjugated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody conjugates
Number of subjects: 0
Study: 16222009

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 258
Study: 11856086

Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg intravenously)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 14
Study: 10438182

Group type: EXPERIMENTAL
Intervention: Rimactane (600 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Generic rifampicin preparations (600 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In vitro dissolution profiles
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Body weight of volunteers
Number of subjects: 19
Study: 7563559

Group type: EXPERIMENTAL
Intervention: 11‐mg/d dose of transdermal nicotine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 22‐mg/d dose of transdermal nicotine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 44‐mg/d dose of transdermal nicotine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 44‐mg/d dose of nicotine patch therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Higher percentage of cotinine replacement
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Week 2 patch dose
Number of subjects: 71
Study: 2346334

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 136

Group type: COMPARATOR
Intervention: Oral methotrexate
Number of subjects: 136

Group type: COMPARATOR
Intervention: 24 Gy cranial irradiation
Number of subjects: 136

Group type: COMPARATOR
Intervention: 18 Gy cranial irradiation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Younger children (<2 years)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Cranial computed tomography abnormalities
Number of subjects: 136
Study: 760750

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-adrenoceptor blockade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30777614

Group type: EXPERIMENTAL
Intervention: Health Heart Tracker (HHT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual patient discharge handouts (Control)
Number of subjects: 84
Study: 27976801

Group type: EXPERIMENTAL
Intervention: Anti-Fla-X positivity at baseline
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Anti-Fla-X positivity at 12 months
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Presence of all four antibacterial antibodies (anti-CBir1, anti-OmpC, anti-A4-Fla2, anti-Fla-X) at baseline
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Baseline quartile sum score for all six antimicrobial antibodies
Number of subjects: 169
Study: 25721604

Group type: EXPERIMENTAL
Intervention: 4xEC-4xDoc
Number of subjects: 772

Group type: COMPARATOR
Intervention: 6xCEF/CMF
Number of subjects: 772
Study: 25306557

Group type: EXPERIMENTAL
Intervention: 100 mg benralizumab
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: 20 mg benralizumab
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: benralizumab (any dose)
Number of subjects: 609

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 609
Study: 22039087

Group type: EXPERIMENTAL
Intervention: Induction oxaliplatin, folinic acid and 5‐FU followed by CRT and surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Preoperative CRT with 5‐fluorouracil (5‐FU) continuous infusion followed by surgery
Number of subjects: 57
Study: 19220764

Group type: EXPERIMENTAL
Intervention: New gustatory stimulant of salivary secretion containing weaker malic acid, fluoride, and xylitol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional citric acid-based gustatory stimulant
Number of subjects: 120
Study: 17241860

Group type: EXPERIMENTAL
Intervention: MMX mesalamine 2.4 g/day
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: MMX mesalamine 4.8 g/day
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: ASACOL 2.4 g/day
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 15066738

Group type: EXPERIMENTAL
Intervention: Tea tree oil regimen (10% cream, 5% body wash for 5 days)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard treatment (mupirocin 2% nasal ointment, chlorhexidine gluconate 4% soap, silver sulfadiazine 1% cream for 5 days)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Mupirocin 2% nasal ointment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Tea tree cream
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Tea tree treatment
Number of subjects: 224
Study: 12086554

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (Kaletra)
Number of subjects: 0
Study: 9585043

Group type: EXPERIMENTAL
Intervention: Scintimammography (740 MBq of Tc-99m sestamibi)
Number of subjects: 70

Group type: COMPARATOR
Intervention: X-ray mammography
Number of subjects: 70
Study: 1888324

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (special kind of behaviour therapy)
Number of subjects: 192

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 192
Study: 6337951

Group type: EXPERIMENTAL
Intervention: Captopril (450 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril (combined with hydrochlorothiazide)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (up to 100 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Captopril monotherapy
Number of subjects: 18
Study: 31201110

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation using intensity-modulated radiotherapy (IMRT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Quality assurance programme
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dosimetry audits for IMRT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Post-trial feedback
Number of subjects: 41
Study: 30367116

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity intervals (VII) at 90% of heart rate reserve (HRR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session of 45 minutes of walking at 45-55% of HRR
Number of subjects: 10
Study: 26453773

Group type: EXPERIMENTAL
Intervention: TDF plus peginterferon for 48 weeks (group A)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B)
Number of subjects: 740

Group type: COMPARATOR
Intervention: TDF for 120 weeks (group C)
Number of subjects: 740

Group type: COMPARATOR
Intervention: peginterferon for 48 weeks (group D)
Number of subjects: 740
Study: 24215302

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 60
Study: 22129616

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 0 ml (V0)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 100 ml (V100)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 300 ml (V300)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 500 ml (V500)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with gastric distension (all volumes)
Number of subjects: 9
Study: 20697246

Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (previous heel sticks without mechanical vibration)
Number of subjects: 20
Study: 18494756

Group type: EXPERIMENTAL
Intervention: Headache Management Program (HMP)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 124
Study: 16805931

Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl with saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl with ketoprofen (1.5 mg kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraoperative remifentanil with saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil with ketoprofen
Number of subjects: 120
Study: 12505963

Group type: EXPERIMENTAL
Intervention: Interscalene group (n = 20) received clonidine 150 micro g in 15 mL of saline through the catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic group (n = 20) received 15 mL of saline through the catheter and clonidine 150 micro g (1 mL) subcutaneously
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interscalene group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 10606932

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 9075128

Group type: EXPERIMENTAL
Intervention: felodipine 5 mg once daily for 4 weeks
Number of subjects: 18
Study: 8371932

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon alpha‐2a (3 million units/m2) every other day for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 20
Study: 3522749

Group type: EXPERIMENTAL
Intervention: Augmentin (amoxycillin-clavulanic acid)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 67
Study: 29447947

Group type: EXPERIMENTAL
Intervention: 80-W GreenLight photoselective vaporization (GL PV)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 238
Study: 27576073

Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program, provider education, and one-on-one coaching of practice-based immunization champions
Number of subjects: 70549

Group type: EXPERIMENTAL
Intervention: Active intervention groups
Number of subjects: 70549

Group type: COMPARATOR
Intervention: Maintenance groups
Number of subjects: 70549

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 70549
Study: 24906043

Group type: EXPERIMENTAL
Intervention: Auto-Disable syringe with a 23 gauge and 25 mm needle
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Disposable syringe with a 24 gauge and 25 mm needle
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both groups (Auto-Disable and Disposable syringes)
Number of subjects: 1000
Study: 21494820

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Non-statin users
Number of subjects: 1458
Study: 20219638

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18984557

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-personalized message source
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-personalized message source
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-tailored outcome expectation
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-tailored outcome expectation
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention with high-depth tailored self-efficacy components
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Web-based smoking cessation intervention with low-depth tailored self-efficacy components
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Sequential exposure to program sections over 5 weeks
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Unified Web program with all sections available at once
Number of subjects: 1866
Study: 15991505

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia alone (Group A1, n=30)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide (Group N1, n=27)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia alone (Group A3, n=23)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide (Group N3, n=22)
Number of subjects: 102
Study: 12410648

Group type: EXPERIMENTAL
Intervention: DDAVP (300 micro g) nasal spray
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10514155

Group type: EXPERIMENTAL
Intervention: Brief behavioural counselling by practice nurses
Number of subjects: 883

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 883
Study: 8792950

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Hydrochlorothiazide 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 1881718

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 6336877

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 733

Group type: COMPARATOR
Intervention: Light exercise (Control)
Number of subjects: 733